1. Resources
  2. Citations Library

Headers act as filters

  • Record
      1. Author :
        Shiota, M.; Zardan, A.; Takeuchi, A.; Kumano, M.; Beraldi, E.; Naito, S.; Zoubeidi, A.; Gleave, M. E.
      2. Title :
      3. Type :
        Journal Article
      4. Year :
        2012
      5. Publication :
        Cancer Res
      6. Products :
      7. Volume :
        72
      8. Issue :
        N/A
      9. Page Numbers :
        N/A
      10. Research Area :
        N/A
      11. Keywords :
        PC-3M-luc-C6, PC-3M-luc, IVIS, Bioware, Prostate cancer, Bioluminescence, Animals; Base Sequence; Blotting, Western; Chromatin Immunoprecipitation; Clusterin/genetics/*physiology; DNA Primers; Epithelial-Mesenchymal Transition/*physiology; Humans; Male; Mice; *Neoplasm Metastasis; Nuclear Proteins/*physiology; Promoter Regions, Genetic; Prostatic Neoplasms/*pathology; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor beta/*physiology; Twist Transcription Factor/*physiology
      12. Abstract :
        TGF-beta promotes epithelial-mesenchymal transition (EMT) and induces clusterin (CLU) expression, linking these genes to cancer metastasis. CLU is a pleiotropic molecular chaperone that confers survival and proliferative advantage to cancer cells. However, the molecular mechanisms by which TGF-beta regulates CLU expression and CLU affects metastasis remain unknown. In this study, we report that the transcription factor Twist1 mediates TGF-beta-induced CLU expression. By binding to E-boxes in the distal promoter region of CLU gene, Twist1 regulated basal and TGF-beta-induced CLU transcription. In addition, CLU reduction reduced TGF-beta induction of the mesenchymal markers, N-cadherin and fibronectin, thereby inhibiting the migratory and invasive properties induced by TGF-beta. Targeted inhibition of CLU also suppressed metastasis in an in vivo model. Taken together, our findings indicate that CLU is an important mediator of TGF-beta-induced EMT, and suggest that CLU suppression may represent a promising therapeutic option for suppressing prostate cancer metastatic progression.
      13. URL :
        http://www.ncbi.nlm.nih.gov/pubmed/22896337
      14. Call Number :
        PKI @ kd.modi @ 7
      15. Serial :
        10540